Plasma Protein Biomarkers of Spirometry Measures of Impaired Lung Function
CHEST · 2025-06 · 167 (6) · 1557-1577
DOI: 10.1016/j.chest.2024.11.012 ↗Kurz gefasst
Fachartikel in der Zeitschrift CHEST, 2025-06. Verfasst von Mohit Aggarwal und 11 weiteren Autor:innen. Beteiligte Einrichtung: Framingham Heart Study, Framingham, MA; Population Sciences Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda…. Hauptthemen laut MEDLINE: Spirometry, Blood Proteins, Lung Diseases, Lung. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, Intramural NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
BACKGROUND: Impaired pulmonary function carries significant risks for lung, cardiovascular, and metabolic disorders. RESEARCH QUESTION: Can circulating protein biomarkers of pulmonary function provide insight into the pathophysiologic features of lung function impairment and links to comorbidities? STUDY DESIGN AND METHODS: We analyzed plasma levels of 2,922 proteins in 32,493 UK Biobank participants (53% female; mean [SD] age, 57 [8] years) to investigate their associations with spirometry measures of lung function (FEV1, FVC, FEV1 to FVC ratio), and with obstructive (n = 4,713) and restrictive (n = 3,886) spirometry patterns. Significant protein signatures were annotated functionally and validated externally in 740 Framingham Heart Study (FHS) participants. We inferred causality using Mendelian randomization and examined colocalization of genetic signals of protein biomarkers with corresponding lung traits. RESULTS: In the UK Biobank, we identified 1,240 proteins associated significantly (P < .000017 observed in the UK Biobank) with FEV1, 1,310 proteins associated significantly with FVC, and 513 proteins associated significantly with FEV1 to FVC ratio. Of these, 44, 99, and 13 proteins, respectively, were nominally significant (P < .01 obeserved in the FHS) in the FHS. Plasma levels of 737 proteins (seven with P < .01 obeserved in the FHS) differed in individuals with an obstructive spirometry pattern (OSP), and 811 proteins (38 with P < .01 obeserved in the FHS) differed in restrictive spirometry pattern compared with normal spirometry in the UK Biobank. Putatively causal relationships to FEV1, FVC, FEV1 to FVC ratio, and OSP were observed for 55, 63, 28, and 14 proteins, respectively. Of note, several circulating decoy receptors, including IL-1 receptor-like 1, tumor necrosis factor receptor superfamily member-6B, and macrophage scavenger receptor-1, emerged as causal and protective biomarkers of lung function. Enrichment analysis suggested a connection between reduced lung function and systemic inflammation driven by adipose tissue dysfunction and gut dysbiosis. Protein biomarkers associated with lung function also were enriched for susceptibility to cardiovascular conditions and cancers. INTERPRETATION: This study identified proteomic signatures of reduced lung function linked to comorbidities, paving the way for improved diagnostics for and treatment of lung disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Framingham Heart Study, Framingham, MA; Population Sciences Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD.
- Pulmonary, Allergy and Critical Care Medicine, Duke University Hospital, Durham, NC.
- Division of Cardiology, Beth Israel Medical Center, Boston, MA.
- Department of Biostatistics, Boston University School of Public Health, Boston, MA; Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, QC, Canada.
- Pfizer Research and Development, Stockholm, Sweden; Department of Medical Epidemiology and Biostatistics, Karolinska Institute, Solna, Sweden.
- Framingham Heart Study, Framingham, MA; Pulmonary Center, Boston University School of Medicine, Boston, MA.
Förderung
- NHLBI NIH HHS
- Intramural NIH HHS
- National Institutes of Health
- National Heart, Lung, and Blood Institute
- Boston University
Zitieren
APA
Aggarwal, M., Hwang, S. J., Lee, D. H., Huan, T., McNeill, J. N., Courchesne, P., Joehanes, R., Ho, J. E., Dupuis, J., Hedman, Å. K., O'Connor, G., & Levy, D. (2025). Plasma Protein Biomarkers of Spirometry Measures of Impaired Lung Function. CHEST, 167(6), 1557-1577. https://doi.org/10.1016/j.chest.2024.11.012
Vancouver
Aggarwal M, Hwang SJ, Lee DH, Huan T, McNeill JN, Courchesne P, et al. Plasma Protein Biomarkers of Spirometry Measures of Impaired Lung Function. CHEST. 2025;167(6):1557-1577. doi:10.1016/j.chest.2024.11.012
BibTeX
@article{Aggarwal2025,
author = {Aggarwal, Mohit and Hwang, Shih-Jen and Lee, Dong Heon and Huan, Tianxiao and McNeill, Jenna N and Courchesne, Paul and Joehanes, Roby and Ho, Jennifer E and Dupuis, Josée and Hedman, Åsa K and O'Connor, George and Levy, Daniel},
title = {Plasma Protein Biomarkers of Spirometry Measures of Impaired Lung Function},
journal = {CHEST},
year = {2025},
volume = {167},
number = {6},
pages = {1557--1577},
doi = {10.1016/j.chest.2024.11.012}
}
EUVIMED